Table 1.
Non-Hispanic White |
Non-Hispanic Black |
Hispanic | Other | p-value | |
---|---|---|---|---|---|
N | 2,103 | 195 | 302 | 192 | |
Characteristics | |||||
Age at metastatic diagnosis | 0.208 | ||||
66-70 | 523 (24.8) | 56 (28.7) | 99 (32.8) | 41 (21.3) | |
71-75 | 546 (25.9) | 47 (24.1) | 69 (22.8) | 55 (28.6) | |
76-80 | 458 (21.8) | 41 (21.0) | 60 (19.9) | 40 (20.8) | |
81+ | 576 (27.4) | 51 (26.2) | 74 (24.5) | 56 (29.1) | |
Sex | 0.699 | ||||
Female | 878 (41.7) | 90 (46.1) | 128 (42.4) | 81 (42.2) | |
Male | 1,225 (58.2) | 105 (53.8) | 174 (57.6) | 111 (57.8) | |
Tumor stage at initial SEER diagnosis | 0.884 | ||||
I | 214 (10.2) | 17 (8.7) | 29 (9.6) | 18 (9.3) | |
II | 68 (3.2) | <11* | <11* | <11* | |
III | 267 (12.7) | 16 (8.2) | 43 (14.2) | 24 (12.5) | |
IV | 1,494 (71.0) | 149 (76.4) | 210 (69.5) | 136 (70.8) | |
Unknown | 60 (2.8) | <11* | <15* | <11* | |
Histology | 0.002 | ||||
Other | 370 (17.6) | 52 (26.7) | 43 (14.2) | 27 (14.1) | |
Clear cell histology | 1,733 (82.4) | 143 (73.3) | 259 (85.8) | 165 (85.9) | |
Married | 1,118 (53.2) | 59 (30.2) | 154 (51.0) | 113 (58.8) | <0.001 |
Lives in metropolitan area | 1,624 (77.2) | 157 (80.5) | 271 (89.7) | 171 (89.1) | <0.001 |
Geographic region | <0.001 | ||||
Midwest | 306 (14.5) | 23 (11.8) | <11* | <11* | |
Other | 183 (8.7) | 28 (14.4) | <11* | <11* | |
Northeast | 493 (23.4) | 26 (13.3) | 26 (8.6) | 18 (9.4) | |
South | 413 (19.6) | 71 (36.4) | <11* | <11* | |
West | 708 (33.7) | 47 (24.1) | 261 (86.4) | 164 (85.4) | |
Dual enrolled | 412 (19.6) | 119 (61.0) | 209 (69.2) | 115 (59.9) | <0.001 |
Highest quartile: black race | 482 (22.9) | 155 (79.5) | 30 (9.9) | 18 (9.4) | <0.001 |
Highest quartile: adults 25+ with less than high school education | 380 (18.1) | 84 (43.1) | 163 (54.0) | 58 (30.2) | <0.001 |
Highest quartile: households living below poverty level | 406 (19.3) | 116 (59.5) | 120 (39.7) | 43 (22.4) | <0.001 |
Nephrectomy in 12 months prior | 0.310 | ||||
Partial | 37 (1.7) | <11* | <11* | <11* | |
Radical | 195 (9.3) | <11* | 30 (9.9) | <20* | |
Myocardial infarction | 213 (10.1) | 24 (12.3) | 28 (9.3) | 20 (10.4) | 0.740 |
Hypertension | 1,801 (85.6) | 185 (94.9) | 256 (84.8) | 171 (89.1) | 0.002 |
Peripheral vascular disease | 564 (26.8) | 72 (36.9) | 74 (24.5) | 51 (26.6) | 0.014 |
Congestive heart failure | 468 (22.2) | 70 (35.9) | 57 (18.9) | 57 (29.7) | <0.001 |
Dementia | 93 (4.4) | <15* | <15* | <11* | 0.873 |
Cardiovascular disease | 482 (22.9) | 59 (30.2) | 68 (22.5) | 41 (21.3) | 0.113 |
Chronic obstructive pulmonary disease | 679 (32.3) | 78 (40.0) | 90 (29.8) | 61 (31.8) | 0.107 |
Cardiovascular disease | 482 (22.9) | 59 (30.3) | 68 (22.5) | 41 (21.3) | 0.113 |
Rheumatologic disease | 104 (4.9) | <11* | 22 (7.3) | <11* | 0.133 |
Peptic ulcer disease | 55 (2.6) | <11* | <15* | <15* | 0.021 |
Mild liver disease | 291 (13.8) | 39 (20.0) | 53 (17.5) | 37 (19.3) | 0.016 |
End stage renal disease | 602 (28.6) | 75 (38.4) | 103 (34.1) | 62 (32.3) | 0.009 |
Diabetes | 815 (38.7) | 118 (60.5) | 171 (56.6) | 104 (54.2) | <0.001 |
Diabetes with complications | 278 (13.2) | 50 (25.6) | 79 (26.1) | 38 (19.8) | <0.001 |
Hemiplegia or paraplegia | 46 (2.2) | <11* | <11* | <11* | 0.070 |
Year of metastatic diagnosis | 0.227 | ||||
2007 | 176 (8.4) | 22 (11.3) | 29 (9.6) | 19 (9.9) | |
2008 | 193 (9.2) | 14 (7.2) | 35 (11.6) | 20 (10.4) | |
2009 | 190 (9.0) | 27 (13.8) | 27 (8.9) | 13 (6.8) | |
2010 | 189 (9.0) | 20 (10.2) | 35 (11.6) | 23 (12.0) | |
2011 | 244 (11.6) | 17 (8.7) | 36 (11.9) | 23 (11.9) | |
2012 | 257 (12.2) | 16 (8.2) | 42 (13.9) | 22 (11.4) | |
2013 | 300 (14.3) | 36 (18.5) | 35 (11.6) | 21 (10.9) | |
2014 | 302 (14.4) | 23 (11.8) | 35 (11.6) | 29 (15.1) | |
2015 | 252 (12.0) | 20 (10.2) | 28 (9.3) | 22 (11.4) |
Cell sizes less than 11 are suppressed in accordance with SEER-Medicare cell size suppression polices